Sands Capital, an investment management company, released its “Sands Capital Select Growth Strategy” Q3 2025 investor letter.

Dexcom has announced that the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for people over the age of 18 with diabetes will launch in the United States on Dec. 1.

American Diversified Holdings Corporation (OTCID: ADHC) announced today that GlucoGuard has completed the Level 2 App integration ...

These two medical device makers have seen huge success in their areas of specialty. DexCom has a profitable and growing CGM ...

Dexcom’s “Smart Basal” has received FDA clearance for people with type 2 diabetes using long-acting insulin. The feature will ...

Dexcom announced the Dexcom G7 15 Day Continuous Glucose Monitoring System for people over the age of 18 with diabetes will ...

At age 72, Nathan Harms still climbs ladders, hauls paint cans and balances on beams – tasks that demand precision, stamina ...

In a phase II trial, type 2 diabetes patients treated with amycretin -- an investigational long-acting GLP-1 and amylin ...

Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Mid Cap Growth Fund” third-quarter ...

Labaton Keller Sucharow LLP ("Labaton") announces that, on November 25, 2025, it filed a securities class action lawsuit (the "Complaint") on behalf of its client Boston Retirement System ("Boston") ...

Adults with type 2 diabetes who used a continuous glucose monitor and wore their sensor for more than 270 days in 1 year had ...

The healthcare industry presents a wealth of opportunities for investors to generate notable portfolio returns over decades.